News
NCNA
0.7500
-5.18%
-0.0410
Weekly Report: what happened at NCNA last week (0331-0404)?
Weekly Report · 1d ago
Weekly Report: what happened at NCNA last week (0324-0328)?
Weekly Report · 03/31 09:05
Weekly Report: what happened at NCNA last week (0317-0321)?
Weekly Report · 03/24 09:04
NuCana’s Mixed Clinical Results and Financial Caution Lead to Hold Rating
TipRanks · 03/21 13:55
NuCana Reports 2024 Financial Results and Advances Cancer Treatment Programs
TipRanks · 03/20 21:27
NuCana reports Q4 loss per share GBP (0.01) vs GBP (.14)
TipRanks · 03/20 20:55
BRIEF-Nucana Reports Fourth Quarter And Year-End 2024 Financial Results And Provides Business Update
Reuters · 03/20 20:49
NuCana Reports Q4 EPS GBP (1) vs. GBP (14)
TipRanks · 03/20 20:20
NUCANA PLC QTRLY SHR LOSS $0.01
Reuters · 03/20 20:01
Weekly Report: what happened at NCNA last week (0310-0314)?
Weekly Report · 03/17 09:05
Weekly Report: what happened at NCNA last week (0303-0307)?
Weekly Report · 03/10 09:05
Weekly Report: what happened at NCNA last week (0224-0228)?
Weekly Report · 03/03 09:05
Weekly Report: what happened at NCNA last week (0217-0221)?
Weekly Report · 02/24 09:05
Weekly Report: what happened at NCNA last week (0210-0214)?
Weekly Report · 02/17 09:05
BRIEF-Nucana PLC's Donald Munoz Departs From His Role As CFO
Reuters · 02/10 13:20
Weekly Report: what happened at NCNA last week (0203-0207)?
Weekly Report · 02/10 09:04
Weekly Report: what happened at NCNA last week (0127-0131)?
Weekly Report · 02/03 09:04
Weekly Report: what happened at NCNA last week (0120-0124)?
Weekly Report · 01/27 09:05
Weekly Report: what happened at NCNA last week (0113-0117)?
Weekly Report · 01/20 09:04
Weekly Report: what happened at NCNA last week (0106-0110)?
Weekly Report · 01/13 09:04
More
Webull provides a variety of real-time NCNA stock news. You can receive the latest news about Nucana through multiple platforms. This information may help you make smarter investment decisions.
About NCNA
More
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.